how big is Global Health?

As of Jun 06, Global Health Ltd has a market capitalization of 32,298.00 Cr, with recent net sales of 3,692.33 Cr and a net profit of 481.44 Cr for the latest four quarters. Shareholder's funds are 2,428.21 Cr, and total assets amount to 4,090.26 Cr as of Mar'23.

Market Cap: As of Jun 06, Global Health Ltd has a market capitalization of 32,298.00 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Global Health reported a sum of Net Sales of 3,692.33 Cr and a sum of Net Profit of 481.44 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'23. Shareholder's Funds are reported at 2,428.21 Cr, while Total Assets amount to 4,090.26 Cr.

Who are in the management team of Global Health?

As of March 2023, the management team of Global Health includes Naresh Kumar Trehan (Chairman & Managing Director), Pankaj Prakash Sahni (Group CEO), and several independent and non-executive directors, ensuring a blend of operational leadership and oversight.

As of March 2023, the management team of Global Health includes the following individuals:<BR><BR>1. Naresh Kumar Trehan - Chairman & Managing Director<BR>2. Pankaj Prakash Sahni - Group CEO & Whole-Time Director<BR>3. Hari S Bhartia - Independent Non-Executive Director<BR>4. Praveen Mahajan - Independent Non-Executive Director<BR>5. Rajan Bharti Mittal - Independent Non-Executive Director<BR>6. Ravi Gupta - Independent Non-Executive Director<BR>7. Ravi Kant Jaipuria - Non-Executive Director / Nominee<BR>8. Sunil Sachdeva - Non-Executive Director<BR>9. Venkatesh Ratnasami - Non-Executive Director / Nominee<BR>10. Vikram Singh Mehta - Independent Non-Executive Director<BR><BR>This team comprises a mix of executive and non-executive directors, with a focus on both operational leadership and independent oversight.

Has Global Health declared dividend?

No Dividend History Available

Who are the peers of the Global Health?

Peers of Global Health include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Aster DM Health, and others. Max Healthcare and Apollo Hospitals show excellent growth and management risk, while Aster DM Health has the highest 1-year return at 78.92%, and Global Health's return is 11.01%.

Peers: The peers of Global Health are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Aster DM Health., Krishna Institu., Rainbow Child., Dr Agarwal's Hea, Jupiter Life Lin, and Health.Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Dr Agarwal's Hea, Krishna Institu., Rainbow Child., Jupiter Life Lin, and Global Health, while Average management risk is found at Fortis Health., Aster DM Health., and Health.Global. Growth is excellent at Max Healthcare and Apollo Hospitals, good at Narayana Hrudaya, Dr Agarwal's Hea, and Global Health, while below average growth is seen at Aster DM Health., Krishna Institu., and Rainbow Child. In terms of capital structure, excellent ratings are given to Max Healthcare, Global Health, Krishna Institu., and Jupiter Life Lin, while average ratings are found at Apollo Hospitals and Fortis Health., and below average at Aster DM Health. and Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aster DM Health. at 78.92%, while the lowest is Dr Agarwal's Hea with N/A, and Global Health's 1-year return is 11.01%. Additionally, Jupiter Life Lin has a negative six-month return of -3.18%.

What does Global Health do?

Global Health Ltd provides healthcare services in the hospital industry and reported net sales of 9,312 Cr and a net profit of 1,014 Cr for the quarter ending March 2025, with a market cap of INR 35,941 Cr. The company, incorporated in 2004 and transitioned to a public limited company in 2021, has a P/E ratio of 69.00 and a return on equity of 15.34%.

Overview: <BR>Global Health Ltd is engaged in providing healthcare services and operates within the hospital industry as a large-cap company.<BR><BR>History: <BR>Global Health Ltd was incorporated as Global Health Private Limited on August 13, 2004, in New Delhi, India. The company transitioned to a Public Limited Company and changed its name to Global Health Limited on August 11, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 9,312 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1,014 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 35,941 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 69.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.12 <BR>Return on Equity: 15.34% <BR>Price to Book: 10.52 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Global Health?

The top shareholders of Global Health include Naresh Trehan with 33.03%, Dunearn Investments (Mauritius) Pte Ltd at 14.86%, 25 mutual fund schemes holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined 11.76%. Individual investors account for 6.53% of the shareholding.

The top shareholders of Global Health include Naresh Trehan, who is the promoter with the highest holding at 33.03%. The highest public shareholder is Dunearn Investments (Mauritius) Pte Ltd, holding 14.86%. Additionally, the company has 25 mutual fund schemes collectively holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined holding of 11.76%. Individual investors account for 6.53% of the shareholding.

Are Global Health latest results good or bad?

Global Health's latest results are positive, with net sales increasing by 10.69% to Rs 1,030.84 crore and profit after tax rising by 22.5% to Rs 159.01 crore, indicating strong financial performance and operational efficiency. The improved debt-equity ratio and earnings per share further reflect the company's commitment to growth and shareholder value.

Global Health's latest results are quite positive, indicating a strong financial performance for the quarter ending June 2025. The company has shown significant improvements across several key metrics. <BR><BR>Net sales reached Rs 1,030.84 crore, marking a 10.69% increase compared to the previous quarter, which is a notable turnaround from the decline experienced earlier. The operating profit also saw a healthy rise, reaching Rs 246.58 crore, and the profit before tax grew by 21.5% compared to the previous average, amounting to Rs 187.68 crore. <BR><BR>Moreover, the profit after tax surged to Rs 159.01 crore, reflecting a remarkable growth of 22.5%. The earnings per share increased to Rs 5.92, showcasing the company's commitment to enhancing shareholder value. <BR><BR>Additionally, the debt-equity ratio improved significantly to 0.21 times, indicating a strategic reduction in borrowing, while the operating profit to interest ratio reached an impressive 17.88 times, suggesting effective management of interest payments. <BR><BR>Overall, these results highlight a period of strong growth and operational efficiency for Global Health, making the latest financial performance very encouraging.

When is the next results date for Global Health?

The next results date for Global Health is 07 November 2025.

The next results date for Global Health is scheduled for 07 November 2025.

Is Global Health overvalued or undervalued?

As of November 19, 2025, Global Health is considered very expensive with a PE ratio of 53.76 and high valuation ratios compared to peers, despite a strong three-year return of 189.89%, indicating it is overvalued in the current market.

As of 19 November 2025, the valuation grade for Global Health has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently deemed overvalued. Key ratios highlight this assessment, with a PE ratio of 53.76, a Price to Book Value of 8.70, and an EV to EBITDA of 33.44, all of which are considerably high compared to industry norms.<BR><BR>In comparison to its peers, Global Health's valuation stands out, particularly when looking at Max Healthcare with a PE of 80.06 and Apollo Hospitals at 64.09. This suggests that while Global Health is indeed very expensive, it is relatively more attractive than some of its peers. Notably, the company has shown a strong return of 189.89% over the past three years, outperforming the Sensex's 38.15% return during the same period, which may contribute to its elevated valuation despite the current market conditions.

How has been the historical performance of Global Health?

Global Health has shown strong financial growth over the past five years, with net sales increasing from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, alongside significant rises in operating profit and profits before and after tax. Despite challenges in cash flow management, the company has expanded its asset base significantly during this period.

Answer:<BR>The historical performance of Global Health shows a consistent upward trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Global Health's net sales have increased significantly from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, reflecting a strong growth trajectory. Total operating income followed a similar pattern, rising from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 222.85 crore in March 2021 to INR 956.17 crore in March 2025. Profit before tax increased from INR 32.46 crore in March 2021 to INR 647.26 crore in March 2025, while profit after tax rose from INR 28.81 crore to INR 481.32 crore during the same period. The earnings per share (EPS) showed fluctuations, peaking at INR 60.79 in March 2023 before settling at INR 17.92 in March 2025. On the balance sheet, total assets grew from INR 2,666.29 crore in March 2021 to INR 4,733.21 crore in March 2025, while total liabilities increased from INR 2,668.36 crore to INR 4,733.21 crore. The cash flow from operating activities improved from INR 241 crore in March 2021 to INR 623 crore in March 2025, although the net cash flow showed a decline, ending at INR -194 crore in March 2025 compared to INR -78 crore in March 2021. Overall, Global Health has demonstrated robust growth in revenue and profitability, alongside an expanding asset base, despite some challenges in cash flow management.

Is Global Health technically bullish or bearish?

As of December 1, 2025, the market trend is neutral with mixed indicators, showing a bearish weekly MACD, mildly bearish monthly MACD, and conflicting signals from moving averages and other indicators, reflecting overall market indecision.

As of 1 December 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bearish, while the monthly MACD is mildly bearish, suggesting a lack of upward momentum. The Bollinger Bands indicate a bearish trend on the weekly and a sideways trend on the monthly, further supporting the neutral outlook. Daily moving averages are mildly bullish, but this is countered by the lack of clear signals from the RSI and the absence of trends in both the Dow Theory and OBV. Overall, the strength of the current stance is weak, reflecting indecision in the market.

Should I buy, sell or hold Global Health?

Which are the latest news on Global Health?

Why is Global Health falling/rising?

As of 04-Dec, Global Health Ltd's stock price is 1,199.90, reflecting a decline of 10.6 points or 0.88%. The stock has been on a downward trend for six consecutive days, underperforming its sector and trading below key moving averages, raising concerns about its valuation despite strong fundamentals.

As of 04-Dec, Global Health Ltd's stock price is falling, currently at 1,199.90, which reflects a decrease of 10.6 points or 0.88%. The stock has been on a downward trend, having lost value for the last six consecutive days, resulting in a total decline of 5% during this period. Despite opening the day with a gain of 3.22% and reaching an intraday high of Rs 1249.45, the stock has faced significant selling pressure, evidenced by its intraday low of Rs 1185.7.<BR><BR>The stock's performance has underperformed its sector by 0.75% today, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 19.73% compared to the 5-day average. <BR><BR>While the company shows strong fundamentals, such as high management efficiency and low debt levels, recent financial results have raised concerns. The flat results reported for September, alongside the lowest return on capital employed (ROCE) at 18.11% and the highest interest expense at Rs 17.11 crore, contribute to a perception of the stock being overvalued. The price-to-book ratio of 8.7 suggests that the stock is trading at a premium compared to its peers, which, combined with a high PEG ratio of 2.4, indicates that the stock may not be a favorable investment at this time.